BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33112540)

  • 1. Effect of Combined Sorafenib/Cisplatinum Treatment on the Autophagy and Proliferation of Hepatocellular Carcinoma hepG2 Cells in Vitro.
    Wang Y; Wang L
    Asian Pac J Cancer Prev; 2020 Oct; 21(10):2853-2857. PubMed ID: 33112540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma.
    Kim MN; Lee SM; Kim JS; Hwang SG
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):809-817. PubMed ID: 31385002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of aloin and metformin enhances the antitumor effect by inhibiting the growth and invasion and inducing apoptosis and autophagy in hepatocellular carcinoma through PI3K/AKT/mTOR pathway.
    Sun R; Zhai R; Ma C; Miao W
    Cancer Med; 2020 Feb; 9(3):1141-1151. PubMed ID: 31830378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic antitumor effect of BRMS1 and sorafenib via inhibition of the PI3K/AKT/mTOR/ERK signaling pathway.
    Jin J; Guo Y; Liu Y; Wang Z; Yang X; Sun S
    Oncol Rep; 2019 Sep; 42(3):1183-1193. PubMed ID: 31233204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capsaicin and sorafenib combination treatment exerts synergistic anti‑hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
    Dai N; Ye R; He Q; Guo P; Chen H; Zhang Q
    Oncol Rep; 2018 Dec; 40(6):3235-3248. PubMed ID: 30272354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydrogen sulfide promotes autophagy of hepatocellular carcinoma cells through the PI3K/Akt/mTOR signaling pathway.
    Wang SS; Chen YH; Chen N; Wang LJ; Chen DX; Weng HL; Dooley S; Ding HG
    Cell Death Dis; 2017 Mar; 8(3):e2688. PubMed ID: 28333142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
    Zhang DM; Liu JS; Deng LJ; Chen MF; Yiu A; Cao HH; Tian HY; Fung KP; Kurihara H; Pan JX; Ye WC
    Carcinogenesis; 2013 Jun; 34(6):1331-42. PubMed ID: 23393227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Morin induces autophagy and apoptosis in hepatocellular carcinoma cells through Akt/mTOR/STAT3 pathway].
    Zhao XY; Tian YY; Liu C; Li YL; Lyu YN; Yu SY; Tian SQ; Pei HL; Zuo ZP; Wang ZB
    Zhongguo Zhong Yao Za Zhi; 2023 Aug; 48(16):4475-4482. PubMed ID: 37802874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
    Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
    J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
    Gedaly R; Angulo P; Chen C; Creasy KT; Spear BT; Hundley J; Daily MF; Shah M; Evers BM
    Anticancer Res; 2012 Jul; 32(7):2531-6. PubMed ID: 22753710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
    Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
    Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
    Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
    Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells.
    Yang J; Pi C; Wang G
    Biomed Pharmacother; 2018 Jul; 103():699-707. PubMed ID: 29680738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy.
    Cao W; Liu X; Zhang Y; Li A; Xie Y; Zhou S; Song L; Xu R; Ma Y; Cai S; Tang X
    Biomed Res Int; 2021; 2021():5556306. PubMed ID: 33987439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Puerarin 6″-O-xyloside suppressed HCC via regulating proliferation, stemness, and apoptosis with inhibited PI3K/AKT/mTOR.
    Li L; Liu JD; Gao GD; Zhang K; Song YW; Li HB
    Cancer Med; 2020 Sep; 9(17):6399-6410. PubMed ID: 32691991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA DCST1-AS1 accelerates the proliferation, metastasis and autophagy of hepatocellular carcinoma cell by AKT/mTOR signaling pathways.
    Li J; Zhai DS; Huang Q; Chen HL; Zhang Z; Tan QF
    Eur Rev Med Pharmacol Sci; 2019 Jul; 23(14):6091-6104. PubMed ID: 31364110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cucurbitacin E shows synergistic effect with sorafenib by inducing apoptosis in hepatocellular carcinoma cells and regulates Jak/Stat3, ERK/MAPK, PI3K/Akt/mTOR signaling pathways.
    Üremiş MM; Üremiş N; Türköz Y
    Steroids; 2023 Oct; 198():109261. PubMed ID: 37355001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
    Lu M; Fei Z; Zhang G
    Biomed Pharmacother; 2018 Jan; 97():1282-1288. PubMed ID: 29156516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining combretastatin A4 phosphate with ginsenoside Rd synergistically inhibited hepatocellular carcinoma by reducing HIF-1α via PI3K/AKT/mTOR signalling pathway.
    Yang X; Gao M; Miao M; Jiang C; Zhang D; Yin Z; Ni Y; Chen J; Zhang J
    J Pharm Pharmacol; 2021 Mar; 73(2):263-271. PubMed ID: 33793802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.